BOB体育

This phase II trial studies how well the addition of olaparib to the usual treatment, temozolomide, works in treating patients with neuroendocrine cancer (pheochromocytoma or paraganglioma) that has spread from where it first started (primary site)鈥�

Investigator

Jonathan A Chatzkel

Status

Accepting Candidates

Ages

12 Years - N/A

Sexes

All

This phase II/III trial examines whether patients who have undergone surgical removal of bladder, but require an additional treatment called immunotherapy to help prevent their bladder cancer from coming back, can be identified by a blood test. Many鈥�

Investigator

Jonathan A Chatzkel

Status

Accepting Candidates

Ages

18 Years - N/A

Sexes

All

This phase III trial uses the Decipher risk score to guide therapy selection. Decipher score is based on the activity of 22 genes in prostate tumor and may predict how likely it is for recurrent prostate cancer to spread (metastasize) to other parts鈥�

Investigator

Jonathan A Chatzkel

Status

Accepting Candidates

Ages

18 Years - N/A

Sexes

Male